A lung-disease drug maker could have a longer runway than many expect as its inhaled therapy reaches more patients and aims for a new use in a hard-to-treat lung condition. The bigger swing is its push into lab-made organs and animal-to-human transplants, but that comes with high-stakes trial, pricing, and competition risks.Read more
A key upcoming study result could let United Therapeutics use its flagship lung drug to treat a much larger group of patients, while the company also pushes into next‑generation delivery methods and even lab‑made organs. The flip side is that heavier competition and all‑or‑nothing trial outcomes could quickly change the growth story if new options win doctors over or studies disappoint.Read more
United Therapeutics looks strong today, but it relies heavily on a small handful of medicines that could face copycat competition as legal protections fade. At the same time, its big bet on lab-made organs could either open a new growth path or turn into a costly, slow-moving project if trials and regulators don’t cooperate.Read more
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
